

Rachel E Miller

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4543598/rachel-e-miller-publications-by-year.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

44
papers

1,537
citations

24
h-index

38
g-index

51
ext. papers

1,967
ext. citations

6.3
avg, IF

5
L-index

#	Paper	IF	Citations
44	The Genesis of Pain in Osteoarthritis: Inflammation as a Mediator of Osteoarthritis Pain.. <i>Clinics in Geriatric Medicine</i> , 2022 , 38, 221-238	3.8	3
43	Pain in the Ehlers-Danlos syndromes: Mechanisms, models, and challenges. <i>American Journal of Medical Genetics, Part C: Seminars in Medical Genetics</i> , 2021 , 187, 429-445	3.1	2
42	Animal Models of Ehlers-Danlos Syndromes: Phenotype, Pathogenesis, and Translational Potential. <i>Frontiers in Genetics</i> , 2021 , 12, 726474	4.5	3
41	The role of intra-articular neuronal CCR2 receptors in knee joint pain associated with experimental osteoarthritis in mice. <i>Arthritis Research and Therapy</i> , 2021 , 23, 103	5.7	4
40	Basic Mechanisms of Pain in Osteoarthritis: Experimental Observations and New Perspectives. <i>Rheumatic Disease Clinics of North America</i> , 2021 , 47, 165-180	2.4	5
39	Neuroimmune interactions and osteoarthritis pain: focus on macrophages. <i>Pain Reports</i> , 2021 , 6, e892	3.5	6
38	Microarray analyses of the dorsal root ganglia support a role for innate neuro-immune pathways in persistent pain in experimental osteoarthritis. <i>Osteoarthritis and Cartilage</i> , 2020 , 28, 581-592	6.2	9
37	An update on targets for treating osteoarthritis pain: NGF and TRPV1. <i>Current Treatment Options in Rheumatology</i> , 2020 , 6, 129-145	1.3	2
36	The innate immune response as a mediator of osteoarthritis pain. <i>Osteoarthritis and Cartilage</i> , 2020 , 28, 562-571	6.2	30
35	Pain-related behaviors and abnormal cutaneous innervation in a murine model of classical Ehlers-Danlos syndrome. <i>Pain</i> , 2020 , 161, 2274-2283	8	6
34	Targeting neurotrophic factors: Novel approaches to musculoskeletal pain. <i>Pharmacology & Therapeutics</i> , 2020 , 211, 107553	13.9	13
33	The nociceptive innervation of the normal and osteoarthritic mouse knee. <i>Osteoarthritis and Cartilage</i> , 2019 , 27, 1669-1679	6.2	21
32	An emerging role for Toll-like receptors at the neuroimmune interface in osteoarthritis. <i>Seminars in Immunopathology</i> , 2019 , 41, 583-594	12	19
31	Peripheral Mechanisms Contributing to Osteoarthritis Pain. <i>Current Rheumatology Reports</i> , 2018 , 20, 9	4.9	39
30	What is new in pain modification in osteoarthritis?. <i>Rheumatology</i> , 2018 , 57, iv99-iv107	3.9	37
29	TRPC5 Does Not Cause or Aggravate Glomerular Disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2018 , 29, 409-415	12.7	29
28	Visualization of Peripheral Neuron Sensitization in a Surgical Mouse Model of Osteoarthritis by In Vivo Calcium Imaging. <i>Arthritis and Rheumatology</i> , 2018 , 70, 88-97	9.5	22

27	Chemokine receptor-7 (CCR7) deficiency leads to delayed development of joint damage and functional deficits in a murine model of osteoarthritis. <i>Journal of Orthopaedic Research</i> , 2018 , 36, 864-875	3.8	10
26	An aggrecan fragment drives osteoarthritis pain through Toll-like receptor 2. <i>JCI Insight</i> , 2018 , 3,	9.9	50
25	Nerve growth factor blockade for the management of osteoarthritis pain: what can we learn from clinical trials and preclinical models?. <i>Current Opinion in Rheumatology</i> , 2017 , 29, 110-118	5.3	34
24	Chemogenetic Inhibition of Pain Neurons in a Mouse Model of Osteoarthritis. <i>Arthritis and Rheumatology</i> , 2017 , 69, 1429-1439	9.5	31
23	CCL2 and CCR2 regulate pain-related behaviour and early gene expression in post-traumatic murine osteoarthritis but contribute little to chondropathy. <i>Osteoarthritis and Cartilage</i> , 2017 , 25, 406-412	6.2	65
22	Spinal microglial activation in a murine surgical model of knee osteoarthritis. <i>Osteoarthritis and Cartilage</i> , 2017 , 25, 718-726	6.2	25
21	Osteoarthritis pain: What are we learning from animal models?. <i>Best Practice and Research in Clinical Rheumatology</i> , 2017 , 31, 676-687	5.3	22
20	Current status of nerve growth factor antibodies for the treatment of osteoarthritis pain. <i>Clinical and Experimental Rheumatology</i> , 2017 , 35 Suppl 107, 85-87	2.2	22
19	Is cannabis an effective treatment for joint pain?. <i>Clinical and Experimental Rheumatology</i> , 2017 , 35 Suppl 107, 59-67	2.2	7
18	Therapeutic effects of an anti-ADAMTS-5 antibody on joint damage and mechanical allodynia in a murine model of osteoarthritis. <i>Osteoarthritis and Cartilage</i> , 2016 , 24, 299-306	6.2	49
17	The Role of Peripheral Nociceptive Neurons in the Pathophysiology of Osteoarthritis Pain. <i>Current Osteoporosis Reports</i> , 2015 , 13, 318-26	5.4	26
16	Translational development of an ADAMTS-5 antibody for osteoarthritis disease modification. <i>Osteoarthritis and Cartilage</i> , 2015 , 23, 1254-66	6.2	75
15	PCSK6-mediated corin activation is essential for normal blood pressure. <i>Nature Medicine</i> , 2015 , 21, 1048-53	5.5	83
14	Delivering heparin-binding insulin-like growth factor 1 with self-assembling peptide hydrogels. <i>Tissue Engineering - Part A</i> , 2015 , 21, 637-46	3.9	23
13	Damage-associated molecular patterns generated in osteoarthritis directly excite murine nociceptive neurons through Toll-like receptor 4. <i>Arthritis and Rheumatology</i> , 2015 , 67, 2933-43	9.5	60
12	Osteoarthritis joint pain: the cytokine connection. <i>Cytokine</i> , 2014 , 70, 185-93	4	141
11	Effects of the combination of microfracture and self-assembling Peptide filling on the repair of a clinically relevant trochlear defect in an equine model. <i>Journal of Bone and Joint Surgery - Series A</i> , 2014 , 96, 1601-9	5.6	24
10	Genetically Engineered Mouse Models Reveal the Importance of Proteases as Osteoarthritis Drug Targets. <i>Current Rheumatology Reports</i> , 2013 , 15, 350	4.9	24

9	Effects of Dexamethasone on Mesenchymal Stromal Cell Chondrogenesis and Aggrecanase Activity: Comparison of Agarose and Self-Assembling Peptide Scaffolds. <i>Cartilage</i> , 2013 , 4, 63-74	3	36
8	CCR2 chemokine receptor signaling mediates pain in experimental osteoarthritis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012 , 109, 20602-7	11.5	167
7	Growth factor delivery through self-assembling peptide scaffolds. <i>Clinical Orthopaedics and Related Research</i> , 2011 , 469, 2716-24	2.2	27
6	Effect of self-assembling peptide, chondrogenic factors, and bone marrow-derived stromal cells on osteochondral repair. <i>Osteoarthritis and Cartilage</i> , 2010 , 18, 1608-19	6.2	75
5	Intraarticular injection of heparin-binding insulin-like growth factor 1 sustains delivery of insulin-like growth factor 1 to cartilage through binding to chondroitin sulfate. <i>Arthritis and Rheumatism</i> , 2010 , 62, 3686-94		50
4	Engineering insulin-like growth factor-1 for local delivery. <i>FASEB Journal</i> , 2008 , 22, 1886-93	0.9	29
3	Mathematical modeling of material-induced blood plasma coagulation. <i>Biomaterials</i> , 2006 , 27, 796-806	15.6	45
2	Plasma coagulation response to surfaces with nanoscale chemical heterogeneity. <i>Biomaterials</i> , 2006 , 27, 208-15	15.6	35
1	Procoagulant stimulus processing by the intrinsic pathway of blood plasma coagulation. <i>Biomaterials</i> , 2005 , 26, 2965-73	15.6	43